Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36373822/
Background: Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene-related peptide (CGRP) signaling molecule, and anti-CGRP medications are used to abort and prevent migraine attacks.
Conclusions: In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well-tolerated preventive treatment for migraine.
"
-
Huma Sheikh, CEO, NY Neurology Medicine, PCDecember 03, 2022Good study, to help determine doses.